SG11201509030TA - Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose - Google Patents

Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Info

Publication number
SG11201509030TA
SG11201509030TA SG11201509030TA SG11201509030TA SG11201509030TA SG 11201509030T A SG11201509030T A SG 11201509030TA SG 11201509030T A SG11201509030T A SG 11201509030TA SG 11201509030T A SG11201509030T A SG 11201509030TA SG 11201509030T A SG11201509030T A SG 11201509030TA
Authority
SG
Singapore
Prior art keywords
myopathic
trehalose
treatment
parenteral administration
neurodegenerative diseases
Prior art date
Application number
SG11201509030TA
Other languages
English (en)
Inventor
Dalia Megiddo
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of SG11201509030TA publication Critical patent/SG11201509030TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201509030TA 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose SG11201509030TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Publications (1)

Publication Number Publication Date
SG11201509030TA true SG11201509030TA (en) 2015-11-27

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509030TA SG11201509030TA (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Country Status (15)

Country Link
US (4) US10493023B2 (es)
EP (2) EP4218769A3 (es)
JP (4) JP6837835B2 (es)
KR (1) KR20160009617A (es)
AU (4) AU2014264228A1 (es)
CA (1) CA2911399A1 (es)
CR (1) CR20150637A (es)
EA (1) EA201501054A1 (es)
HK (1) HK1217300A1 (es)
IL (1) IL241757B (es)
MD (1) MD20150120A2 (es)
MX (1) MX2015015355A (es)
PE (1) PE20160012A1 (es)
SG (1) SG11201509030TA (es)
WO (1) WO2014181333A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
KR20160009617A (ko) 2013-05-07 2016-01-26 바이오 블라스트 파마 리미티드 트레할로스의 비경구 투여에 의한 단백질 응집 근병증 및 신경퇴행성 질환의 치료
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
JP6983181B2 (ja) * 2016-02-08 2021-12-17 ジュナクソ，インコーポレーテッド 神経性疾患を治療するためのトレハロースの使用
AU2017252563B2 (en) 2016-04-21 2022-07-21 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
JP7082186B2 (ja) 2017-08-14 2022-06-07 プリレニア ニューロセラピューティクス リミテッド プリドピジンによる筋萎縮性側索硬化症の治療方法
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
CA3167214A1 (en) * 2020-02-13 2021-08-19 Michal Geva Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2022013940A1 (ja) * 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS516109B2 (es) 1972-12-28 1976-02-25
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) * 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
JP2006514954A (ja) * 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物
CN1761450B (zh) 2003-02-13 2010-05-05 株式会社林原生物化学研究所 特征在于含有α,α-海藻糖的糖类衍生物的皮肤外用剂
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
AU2006247351A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
EP1932530A4 (en) 2005-08-11 2009-04-29 Hayashibara Biochem Lab MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE
WO2007063902A1 (ja) 2005-11-30 2007-06-07 The Nisshin Oillio Group, Ltd. トレハロース脂肪酸エステル組成物
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
ES2362940T3 (es) 2006-03-27 2011-07-15 Otsuka Chemical Co., Ltd. Compuesto de trehalosa y producto farmacéutico que comprende dicho compuesto.
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
WO2008093700A1 (ja) 2007-01-31 2008-08-07 Otsuka Chemical Co., Ltd. トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤
WO2008102563A1 (ja) * 2007-02-23 2008-08-28 Next21 K.K. 血管攣縮の治療剤又は予防剤
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CA2703946A1 (en) 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
US8741871B2 (en) 2008-10-31 2014-06-03 Glytech, Inc. Trehalose compound, method for producing same, and pharmaceutical product containing the compound
US20110293605A1 (en) * 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) * 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
WO2012061907A2 (en) * 2010-11-10 2012-05-18 Katholieke Universiteit Leuven Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
KR20160009617A (ko) 2013-05-07 2016-01-26 바이오 블라스트 파마 리미티드 트레할로스의 비경구 투여에 의한 단백질 응집 근병증 및 신경퇴행성 질환의 치료
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof

Also Published As

Publication number Publication date
US10493023B2 (en) 2019-12-03
AU2020277197A1 (en) 2020-12-24
CA2911399A1 (en) 2014-11-13
AU2023200303A1 (en) 2023-02-23
MX2015015355A (es) 2016-07-18
EP2994145A2 (en) 2016-03-16
AU2014264228A1 (en) 2015-11-12
CR20150637A (es) 2016-04-05
US20190374463A1 (en) 2019-12-12
IL241757B (en) 2020-05-31
AU2019204513A1 (en) 2019-07-18
HK1217300A1 (zh) 2017-01-06
WO2014181333A3 (en) 2015-01-08
PE20160012A1 (es) 2016-02-14
US20220117883A1 (en) 2022-04-21
WO2014181333A2 (en) 2014-11-13
EP4218769A2 (en) 2023-08-02
US20240009113A1 (en) 2024-01-11
US20160120798A1 (en) 2016-05-05
EP2994145B1 (en) 2023-01-04
US10869831B2 (en) 2020-12-22
EP4218769A3 (en) 2023-10-18
JP6837835B2 (ja) 2021-03-03
AU2019204513B2 (en) 2020-09-10
JP2019142907A (ja) 2019-08-29
EA201501054A1 (ru) 2016-04-29
JP2016518403A (ja) 2016-06-23
JP2021152032A (ja) 2021-09-30
MD20150120A2 (ro) 2016-03-31
KR20160009617A (ko) 2016-01-26
JP2023040211A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
IL274646A (en) Integrated continuous production of medicinal substances from medical protein
HK1217300A1 (zh) 通過腸胃外施用海藻糖來治療蛋白聚集肌病和神經變性疾病
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HK1220916A1 (zh) 治療癌症和預防癌症藥物抗性的方法
HK1214533A1 (zh) 治療癌症和預防癌症耐藥性的方法
HK1219231A1 (zh) 治療兒童實體瘤的方法
HK1213180A1 (zh) 治療和預防癌症藥物抗性的方法
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
HK1211235A1 (en) Methods of treating cancer and preventing drug resistance
HUE052233T2 (hu) Nem immunszuppresszív, antigénre specifikus immunterápiás ágensek ismételt beadása
IL284969A (en) Diagnosis and treatment of autoimmune diseases
HK1220352A1 (zh) 和神經變性疾病的治療
EP2967062A4 (en) DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
IL239629B (en) History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins
EP3068492A4 (en) Neurodegenerative disorders and methods of treatment and diagnosis thereof
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
GB201318170D0 (en) Proteins with Diagnostic and Therapeutic Uses
HK1220127A1 (zh) 自身免疫性疾病的治療
EP2943593A4 (en) DIAGNOSIS AND TREATMENT OF VIRUS DISEASES
GB201319437D0 (en) Delivery of drugs
GB201321628D0 (en) Treatment of disease
GB201319165D0 (en) New disease modifying therapy of neurodegenerative diseases
GB201301072D0 (en) Therapeutic Moisturiser
GB201300778D0 (en) Therapeutic moisturiser